Three different considerations arise from the present study: the first is related to several difficulties regarding the study of wasteosome composition, the second is linked to the presence of tau in wasteosomes from AD patients, and the third is related to the possible use of wasteosomes as a source of biomarkers for neurodegenerative diseases. The gene discussed is MAPT; the disease is Alzheimer disease.